Literature DB >> 18832458

KRAS mutations: an old oncogene becomes a new predictive biomarker.

Gregory J Riely1, Marc Ladanyi.   

Abstract

This commentary highlights a novel assay for detection of mutations in KRAS, which have recently emerged as a useful negative predictive biomarker.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18832458      PMCID： PMC2570631          DOI： 10.2353/jmoldx.2008.080105

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN： 1525-1578            Impact factor:   5.568


  26 in total

1.  Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.

Authors:  Sae-Won Han; Tae-You Kim; Yoon Kyung Jeon; Pil Gyu Hwang; Seock-Ah Im; Kyung-Hun Lee; Jee Hyun Kim; Dong-Wan Kim; Dae Seog Heo; Noe Kyeong Kim; Doo Hyun Chung; Yung-Jue Bang
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.

Authors:  David M Jackman; Beow Y Yeap; Neal I Lindeman; Panos Fidias; Michael S Rabin; Jennifer Temel; Arthur T Skarin; Matthew Meyerson; Alison J Holmes; Ana M Borras; Boris Freidlin; Patricia A Ostler; Joan Lucca; Thomas J Lynch; Bruce E Johnson; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

3.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

Review 4.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Authors:  Lecia V Sequist; Daphne W Bell; Thomas J Lynch; Daniel A Haber
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

5.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

6.  Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Wilbur A Franklin; Rafal Dziadziuszko; Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Claire Watkins; Angela Flannery; Gillian Ellison; Emma Donald; Lucy Knight; Dinah Parums; Nicholas Botwood; Brian Holloway
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

7.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

8.  Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

Authors:  Silvia Benvenuti; Andrea Sartore-Bianchi; Federica Di Nicolantonio; Carlo Zanon; Mauro Moroni; Silvio Veronese; Salvatore Siena; Alberto Bardelli
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

9.  Genetic predictors of MEK dependence in non-small cell lung cancer.

Authors:  Christine A Pratilas; Aphrothiti J Hanrahan; Ensar Halilovic; Yogindra Persaud; Junichi Soh; Dhananjay Chitale; Hisayuki Shigematsu; Hiromasa Yamamoto; Ayana Sawai; Manickam Janakiraman; Barry S Taylor; William Pao; Shinichi Toyooka; Marc Ladanyi; Adi Gazdar; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

10.  KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

Authors:  William Pao; Theresa Y Wang; Gregory J Riely; Vincent A Miller; Qiulu Pan; Marc Ladanyi; Maureen F Zakowski; Robert T Heelan; Mark G Kris; Harold E Varmus
Journal:  PLoS Med       Date:  2005-01-25       Impact factor: 11.069
View more
  20 in total

Review 1.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

Review 2.  Pleural involvement in lung cancer.

Authors:  Theodora Agalioti; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 3.  Non-small cell lung cancer: current treatment and future advances.

Authors:  Cecilia Zappa; Shaker A Mousa
Journal:  Transl Lung Cancer Res       Date:  2016-06

4.  Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.

Authors:  Badi El Osta; Madhusmita Behera; Sungjin Kim; Lynne D Berry; Gabriel Sica; Rathi N Pillai; Taofeek K Owonikoko; Mark G Kris; Bruce E Johnson; David J Kwiatkowski; Lynette M Sholl; Dara L Aisner; Paul A Bunn; Fadlo R Khuri; Suresh S Ramalingam
Journal:  J Thorac Oncol       Date:  2019-02-05       Impact factor: 15.609

5.  Longitudinal molecular characterization of endoscopic specimens from colorectal lesions.

Authors:  Petra Minarikova; Lucie Benesova; Tereza Halkova; Barbora Belsanova; Stepan Suchanek; Jiri Cyrany; Inna Tuckova; Jan Bures; Miroslav Zavoral; Marek Minarik
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

6.  A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma.

Authors:  Bárbara Angulo; Elena García-García; Rebeca Martínez; Ana Suárez-Gauthier; Esther Conde; Manuel Hidalgo; Fernando López-Ríos
Journal:  J Mol Diagn       Date:  2010-03-04       Impact factor: 5.568

7.  5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Authors:  K Bracht; A M Nicholls; Y Liu; W F Bodmer
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

8.  KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.

Authors:  Shuji Ogino; Jeffrey A Meyerhardt; Natsumi Irahara; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

9.  A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC.

Authors:  Silvia Moreno; Mario Bonfante; Eduardo Zurek; Dmitry Cherezov; Dmitry Goldgof; Lawrence Hall; Matthew Schabath
Journal:  Tomography       Date:  2021-04-29

Review 10.  Ganetespib: research and clinical development.

Authors:  Komal Jhaveri; Shanu Modi
Journal:  Onco Targets Ther       Date:  2015-07-24       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.